Gufic Biosciences has targeted to capture major share of Rs 3000 crore lyophilized antibacterial market in India. Gufic has launched New Drug Delivery System: Dual Chamber Bags at affordable price for the first time in India.
Contributing immensely to the government's ambitious Make in India drive, Gufic has collaborated with its European counterpart to manufacture this new technology indigenously in India. Until now the dual chamber bags have been largely imported in India at a very high cost to the patients. On the contrary, Gufic has not only launched high-quality Dual Chamber Bags at an affordable and pocket friendly price, these New Drug Delivery System products even have longer shelf -life.
Gufic Biosciences is engaged in diversified business viz. Pharma, Healthcare, Bio- Technology, Seeds, Herbal etc.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: